CS
RARX
Candriam SCA’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-99,523
| Closed | -$4.57M | – | 896 |
|
|
2020
Q1 | $4.57M | Hold |
99,523
| – | – | 0.05% | 372 |
|
|
2019
Q4 | $4.67M | Sell |
99,523
-1,128,477
| -92% | -$53M | 0.05% | 379 |
|
|
2019
Q3 | $29M | Buy |
1,228,000
+50,000
| +4% | +$1.18M | 0.38% | 51 |
|
|
2019
Q2 | $35.3M | Buy |
1,178,000
+154,000
| +15% | +$4.61M | 0.44% | 44 |
|
|
2019
Q1 | $22.9M | Buy |
1,024,000
+145,000
| +16% | +$3.25M | 0.29% | 74 |
|
|
2018
Q4 | $16M | Buy |
879,000
+444,000
| +102% | +$8.08M | 0.25% | 91 |
|
|
2018
Q3 | $7.87M | Buy |
435,000
+285,000
| +190% | +$5.16M | 0.1% | 226 |
|
|
2018
Q2 | $1.49M | Sell |
150,000
-1,000
| -0.7% | -$9.95K | 0.02% | 536 |
|
|
2018
Q1 | $802K | Hold |
151,000
| – | – | 0.01% | 624 |
|
|
2017
Q4 | $1.28M | Buy |
151,000
+35,000
| +30% | +$298K | 0.02% | 534 |
|
|
2017
Q3 | $1.69M | Buy |
116,000
+35,000
| +43% | +$511K | 0.03% | 485 |
|
|
2017
Q2 | $1.52M | Buy |
+81,000
| New | +$1.52M | 0.03% | 510 |
|